


Product Name : VX-11e
Catalog Number : T3166
CAS Number : 896720-20-0
Molecular Formula : C₂₄H₂₀Cl₂FN₅O₂
Molecular Weight : 500.35



Description: VX-11e is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.

Storage: 2 years -80°C in solvent; 3 years -20°C powder;

| | | |
|-------------------|--|--------------------|
| Solubility | DMSO | 50 mg/mL (100 mM) |
| | Ethanol | 12.5 mg/mL (25 mM) |
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) | |

| | | |
|------------------------|----------|-----------|
| Receptor (IC50) | Aurora A | 540nM(Ki) |
| | CDK2 | 850nM(Ki) |
| | ERK2 | <2nM(Ki) |
| | FLT3 | 1.4µM(Ki) |
| | GSK-3 | 400nM(Ki) |

In vitro Activity

In HT29 cells, VX-11e potently inhibits cell proliferation with IC₅₀ of 48 nM. [1]

In vivo Activity

In both rats and mice, VX-11e shows good oral bioavailability. [1] In NSG mice bearing human melanoma RPD_X tumors, VX-11e (50 mg/kg, p.o.) results in robust inhibition of pRSK, and inhibits tumor growth. When used in combination with BKM120, VX-11e results in significantly improved tumor growth inhibition. [2]

Kinase Assay

ERK Inhibition Assay: Compounds are assayed for the inhibition of ERK2 by a spectrophotometric coupled-enzyme assay. In this assay, a fixed concentration of activated ERK2 (10 nM) is incubated with various concentrations of the compounds in DMSO (2.5%) for 10 min. at 30 °C in 0.1 M HEPES buffer, pH = 7.5, containing 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200 µM NADH, 150 µg/mL pyruvate kinase, 50 µg/mL lactate dehydrogenase and 200 µM erktide peptide. The reaction is initiated by the addition of 65 µM ATP. The rate of decrease of absorbance at 340 nM is monitored. The IC₅₀ is evaluated from the data as a function of inhibitor concentr

Cell Assay

Cell proliferation is measured by 3H-thymidine incorporation. The cells are plated at a concentration of 10,000 cells/well in a 96-well plate using growth media, RPMI 1640 containing 10% FBS. Serially diluted compounds are added. The cells and compounds are incubated for 48 hours at 37°C incubator. After 48 hours, 0.4 µCi of 3H-thymidine is added to each wells for 8 hours and returned to the 37°C incubator. The cells are harvested using a Tomtec 96-well cell harvester and the CPM is determined using the Wallac 1205 BETAPLATE liquid scintillation counter. The IC₅₀ is the 50% inhibition of contr(Only for Reference)

Cell line: HT29 cells

Animal Experiment

Animal Model: NSG mice bearing human melanoma RPD_X tumors

Reference

1. Aronov AM, et al. J Med Chem. 2009, 52(20), 6362-6368.
2. Krepler C, et al. Clin Cancer Res. 2015. pii: clincanres.1762. 2015

FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data sheet.